ArticleJournal of proteome research2026
MPOInt: An Epigenetics-Driven Workflow for Integrative Multi-Level Proteomics.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteomics provides key insights into systems regulating cell behavior and can elucidate key epigenetic states influencing biological functions in health and disease. Integrating different modalities of proteomics (total, phospho, epi) allows for a comprehensive understanding of how systems change in response to a stimulus. A current limitation is that these data are often captured individually with a limited scope of how systems regulating biological processes interact. Integrative analyses are essential to accurately depict biological states but often require custom, time-consuming bioinformatics processing. The MPOInt pipeline and its associated R package provide highly flexible analysis modules that can be easily combined to develop a multidimensional view of the input data with minimal barrier to entry, and is capable of integrating histone proteome data with known epigenetic effectors. Using this tool and pre-existing clinical data, we identify several pathways that may be targets in driving the growth of aggressive cancers, including treatment-resistant estrogen receptor-positive breast cancer. Overall, MPOInt adds clinical context to data that is traditionally difficult to interpret and generates a unique network centered around epigenetic factors for each collection of data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.